Zeiss Medical Technology announced today that it received CE mark approval for its Cirrus PathFinder clinical support tool.
Cirrus PathFinder utilizes AI to enable more confident decision-making and accelerate workflows with OCT interpretation assistance. It uses proprietary deep learning algorithms to automatically identify abnormal macular OCT B-scans. The software release also provides AI-enhanced OCTA image quality and multi-layer segmentation.
Zeiss said its new offering enables ophthalmologists with powerful, AI-driven capabilities.
Cirrus with PathFinder delivers high-speed image capture with HD imaging detail, a wide field of view and AI decision support. It helps clinicians make more informed and efficient decisions.
Without requiring export and data analysis from third-party platforms, Cirrus PathFinder’s fully integrated AI decision support algorithm interprets data within the clinician’s current workflow. This enables the assessment of hundreds of scans at once, in real time.
The software provides AI-enhanced visualization of the vascular structure and B-scan averaging of the OCTA structural scans. Increased layer segmentation further enhances diagnostic capabilities as well, the company says.
Zeiss plans to offer Cirrus PathFinder via license through its new Cirrus software update, available in select markets.
“At Zeiss, we continue to develop digital diagnostic tools that help streamline workflows, lower costs, improve outcomes, and elevate the patient experience,” says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at Zeiss Medical Technology. “The AI decision support capabilities of Zeiss Cirrus PathFinder help enable faster, more informed and actionable diagnostics for a better clinical and patient experience.”
